Status:
WITHDRAWN
cDC1 Prognostic and Predictive Role in Non-Small-Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
Lead Sponsor:
University Hospital, Grenoble
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The response rate of immune checkpoint inhibitors remains relatively low and the identification of the new predictive biomarkers is necessary. The rare population of cDC1 is very interesting, as its m...
Detailed Description
Multicenter study aiming to collect patient's clinical data retrospectively and their histological samples prospectively. The cohort will include: * 30 patients PD-L1 \> 50% treated with pembrolizum...
Eligibility Criteria
Inclusion
- NSCLC diagnosis
- Advanced disease (Stage III-IV) according to the TNM 7th/8th classification
- Patients have to have performed pembrolizumab in first line if PD-L1 ≥ 50% or cisplastin-based chemotherapy if PD-L1 \< 50%
- FFPE material available from diagnostic sample
Exclusion
- \-
Key Trial Info
Start Date :
June 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04069442
Start Date
June 1 2020
End Date
September 1 2020
Last Update
April 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Grenoble-Alpes
Grenoble, Isère, France, 38043